Venous Thromboembolism

Patients who continued to use anticoagulant therapy beyond the initial 3 to 6 months of treatment for a first unprovoked venous thromboembolism were at “considerable” risk for major bleeding, researchers wrote.

Risk for venous thromboembolism does not differ for women using oral conjugated equine estrogen vs. oral or transdermal estradiol, according to a study published in Menopause.

Patients hospitalized with COVID-19 remain at higher risk for thromboembolic events and death after discharge than previously thought, according to study results published in Blood.

New research showed that hospitalized patients with COVID-19 who received therapeutic full-dose heparin were less likely to die than those who received prophylactic low-dose heparin. It was the top story in hematology/oncology last week.

TV or not TV: The relationship between viewing it and venous thromboembolism risk, when accounting for physical activity and other risk factors, is the question.

A single IV dose of the factor XI monoclonal antibody abelacimab appeared superior to daily enoxaparin for preventing venous thromboembolism after total knee arthroplasty, according to randomized study results.

The FDA approved dabigatran etexilate oral pellets for multiple indications.

Patients with cancer have a five- to sevenfold increased risk for venous thromboembolism compared with patients without cancer, and chemotherapy increases the risk by 6.5-fold.

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results.

Patients with cancer may be at high risk for venous thromboembolism and arterial thromboembolic events while undergoing treatment with immune checkpoint inhibitors, according to study results published in Blood.